Cutaneous sarcoidosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:04 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cutaneous sarcoidosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Sirolimus for Adults with Facial Skin Sarcoidosis: Evaluating Treatment for Moderate to Severe Cases https://clinicaltrials.eu/trial/study-on-sirolimus-for-adults-with-facial-skin-sarcoidosis-evaluating-treatment-for-moderate-to-severe-cases/ Wed, 29 Apr 2026 15:00:53 +0000 https://clinicaltrials.eu/trial/study-on-sirolimus-for-adults-with-facial-skin-sarcoidosis-evaluating-treatment-for-moderate-to-severe-cases/ This clinical trial is focused on studying the effects of a medication called Sirolimus on a condition known as sarcoidosis, specifically when it affects the skin on the face. Sarcoidosis is a disease that causes small clusters of inflammatory cells, called granulomas, to form in different parts of the body, including the skin. In this study, the goal is to see how effective Sirolimus is in treating moderate to severe cases of facial skin involvement in sarcoidosis.

Participants in the study will take Sirolimus in the form of a coated tablet, which is taken orally. The study will last for a period of 16 weeks. During this time, researchers will monitor the participants to see if there is a significant improvement in their skin condition. This will be assessed by looking at changes in the appearance of the skin and evaluating the overall quality of life related to their skin condition. The study will also keep track of any side effects that may occur, such as mouth ulcers or changes in blood cell counts.

The purpose of this study is to evaluate the safety and effectiveness of Sirolimus in treating facial skin sarcoidosis. By the end of the study, researchers hope to determine whether Sirolimus can provide a significant clinical response, which means a noticeable improvement in the skin condition of the participants. This information could help in developing better treatment options for people with sarcoidosis affecting the skin on their face.

]]>